• The funding brings the company’s total tally to $54 million
• ReviR Therapeutics was founded in 2021
• Lapam Capital invests in early to mid-stage pharmaceutical and medical device companies

ReviR Therapeutics, a Brisbane, California-based AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, has raised $30 million in Series A financing.

Lapam Capital led the round. Other backers included CDH Investments, 5Y Capital, and Yael Capital.

These funds will be used to further augment ReviR’s AI-driven drug discovery VoyageR platform, and to support clinical development of treatments for Huntington’s disease, amyotrophic lateral sclerosis and other neurological disorders.

The funding brings the company’s total tally to $54 million.

On the funding, Zhihua Yu, founding partner of Lapam Capital, said in a statement, “Small molecule targeting RNA represents a highly challenging and innovative field. RNA targets offer greater potential compared to protein targets, but also present higher development difficulties. We have great confidence in ReviR’s platform, which can identify potential RNA targets and efficiently develop safe and effective RNA-targeted therapies. This enables the development of orally administrable small molecule drugs for previously undruggable targets.”

ReviR Therapeutics was founded in 2021.

Lapam Capital invests in early to mid-stage pharmaceutical and medical device companies.